AOC3 and diabetic kidney disease: ASP8232 is a small molecule VAP-1 inhibitor that was evaluated for the treatment of diabetic kidney disease (DKD) as an add-on to first-line antihypertensive therapy in a Phase 2 study (ALBUM study).